1. Lessons Learned in the Management of Advanced Pancreatic Cancer
   Eric Van Cutsem et al, 2007, JCO CrossRef
2. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
   Malcolm J. Moore et al, 2007, J. Clin. Oncol. CrossRef
3. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
   Meng Guo et al, 2016, IJMS CrossRef
4. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies
   Tasuku Matsuoka, 2016, WJG CrossRef
5. Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report
   Jing Zhao et al, 2015, WJG CrossRef
6. New targeted therapies in pancreatic cancer
   Andrada Seicean, 2015, WJG CrossRef
7. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line
   Ying-Ying Lu et al, 2008, WJG CrossRef
8. Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma
   Kwang Yeol Paik, 2012, WJGO CrossRef
9. A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model.
   Guang Wu et al, 2018, Int J Mol Sci CrossRef
10. Degalactotigonin, a Steroidal Glycoside from Solanum nigrum, Induces Apoptosis and Cell Cycle Arrest via Inhibiting the EGFR Signaling Pathways in Pancreatic Cancer Cells
    Hoang Le Tuan Anh et al, 2018, BioMed Research International CrossRef
11. Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy
    Bayan Al-Share et al, 2021, Cancer Metastasis Rev CrossRef
12. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
    Darya Javadrashid et al, 2021, Biomedicines CrossRef
13. Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy
    Cristiana Maria Grapa et al, 2021, Materials CrossRef
14. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
    Christopher Montemagno et al, 2021, IJMS CrossRef
15. Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway
    Huiting Xu et al, 2021, Front. Oncol. CrossRef
16. Novel systemic treatment approaches for metastatic pancreatic cancer
    Klara Dorman et al, 2022, Expert Opinion on Investigational Drugs CrossRef
17. Apoptosis-inducing effect of erlotinib is potentiated by 3,3′-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer
    Shadan Ali et al, 2008 CrossRef
18. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Christel Larbouret et al, 2007, Clin. Cancer Res. CrossRef
19. A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer
    Neil E. Martin et al, 2004 CrossRef
20. Pancreatic Cancer Cell Radiation Survival and Prenyltransferase Inhibition: The Role of K-Ras
    Thomas B. Brunner et al, 2005 CrossRef
21. Identification and validation the predictive biomarkers based on risk-adjusted control chart in gemcitabine with or without erlotinib for pancreatic cancer therapy
    Aijun Zhao et al, 2024, Front. Genet. CrossRef